Protocol CTP-BSO -[ADDRESS_321735] : BeShape OneTM  
Protocol Number : CTP-BSO -001 
Development Phase : Clinical Validation  
Sponsor :  BeShape Technologies Ltd.  
Hataas 20, Kfar Saba  
Israel  
Protocol Approval Date : 3-Nov-2022 
Current protocol Version : 5.1 
 
 
 
 
This clinical study will be conducted in accordance with current Good Clinical Practice (GCP) as 
directed by [CONTACT_264748] (ICH); Israel 
Ministry of Health; [LOCATION_002] (US) Code of Federal Regulations (CFR) and the Sponsor’s 
Standard Operating Procedures (SOPs).  
This document contains confidential and proprietary information (including confidential 
commercial information pursuant to 21CFR§20.61) and is a confidential communication of 
BeShape Technologies Ltd.  (the “Sponsor”).  The recipi[INVESTIGATOR_264742].  
 
 
 
 
 
 
Protocol CTP-BSO -[ADDRESS_321736] 2024  
2 
 TABLE OF CONTENTS  
TABLE OF CONTENTS  ................................ ................................ ................................ ................................ .... 2 
PROTOCOL SYNOPSIS  ................................ ................................ ................................ ................................ .... 4 
1 INTRODUCTION ................................ ................................ ................................ ...........................  8 
2 DEVICE DESCRIPTION  ................................ ................................ ................................ .............  10 
2.1 General Device Description  ................................ ................................ ................................ ..........  10 
3 INTENDED USE AND INDICATIONS FOR USE  ................................ ................................ ..... 10 
4 RATIONALE FOR STUDY  ................................ ................................ ................................ .........  10 
5 STUDY OBJECTIVES AND ENDPOINTS  ................................ ................................ ................  11 
5.1 Primary Endpoint  ................................ ................................ ................................ ..........................  11 
5.2 Secondary Endpoints  ................................ ................................ ................................ .....................  11 
5.3 Exploratory Endpoint  ................................ ................................ ................................ ....................  11 
5.4 Safety Endpoint  ................................ ................................ ................................ .............................  11 
6 SELECTION OF STUDY POPULATION  ................................ ................................ ...................  11 
6.1 Inclusion Criteria: ................................ ................................ ................................ ..........................  12 
6.2 Exclusion Criteria ................................ ................................ ................................ ..........................  12 
6.3 Informed Consent  ................................ ................................ ................................ ..........................  13 
7 STUDY DESIGN  ................................ ................................ ................................ ..........................  13 
8 ADMINISTRATION OF TREATMENT  ................................ ................................ .....................  13 
9 STUDY PROCEDURES ................................ ................................ ................................ ...............  14 
9.1 Overview  ................................ ................................ ................................ ................................ ....... 14 
9.2 Screening  ................................ ................................ ................................ ................................ ....... 14 
9.3 Baseline  ................................ ................................ ................................ ................................ .........  15 
9.4 Treatment  ................................ ................................ ................................ ................................ ...... 15 
9.5 Follow -Up ................................ ................................ ................................ ................................ ..... 15 
9.6 Clinical Assessments  ................................ ................................ ................................ .....................  15 
9.6.1  Patient Improvement using the Global Aesthetic Improvement Scale  ...........................  15 
9.6.2  Patient Satisfaction using a 5 -point Likert  Scale  ................................ ............................  15 
9.6.3  Investigator Satisfaction using the Clinical Global Aesthetic Scale  ...............................  15 
9.6.4  Pain Rating Scale  ................................ ................................ ................................ ...........  15 
9.6.5  Abdominal Fat Thickness Measurements  ................................ ................................ ....... 15 
10 PATIENT COMPLETION / WITHDRAWAL  ................................ ................................ .............  16 
10.1 Completion  ................................ ................................ ................................ ................................ .... 16 
10.2 Withdrawal from the study  ................................ ................................ ................................ ............  16 
11 STATISTICAL CONSIDERATIONS  ................................ ................................ ..........................  16 
11.1 Study Design and Objectives  ................................ ................................ ................................ ........  16 
11.2 Study Endpoints  ................................ ................................ ................................ ............................  16 
11.2.1  Primary Endpoint  ................................ ................................ ................................ ...........  16 
11.2.2  Secondary Endpoints  ................................ ................................ ................................ ...... 16 
11.2.3  Exploratory Endpoint  ................................ ................................ ................................ ..... 17 
11.2.4  Safety Endpoints  ................................ ................................ ................................ ............  17 
11.3 Statistical Hypothesis  ................................ ................................ ................................ ....................  17 
11.4 Sample Size Determination  ................................ ................................ ................................ ...........  17 
11.5 Analysis Data Sets ................................ ................................ ................................ .........................  17 
11.5.1  Safety Analysis Set  ................................ ................................ ................................ .........  17 
11.5.2  Full Analysis Set (FAS)  ................................ ................................ ................................ . [ADDRESS_321737] 2024  
3 
 11.5.3  Per Protocol (PP) Analysis Set  ................................ ................................ .......................  17 
11.6 Statistical Methods  ................................ ................................ ................................ ........................  17 
11.6.1  Randomization  ................................ ................................ ................................ ...............  17 
11.6.2  Disposition of Subjects/Data  ................................ ................................ ..........................  17 
11.6.3  Demographic and Baseline Characteristics  ................................ ................................ .... 18 
11.6.4  Efficacy Analyses  ................................ ................................ ................................ ...........  18 
11.6.5  Safety Analyses  ................................ ................................ ................................ ..............  18 
12 SAFETY, ADVERSE EVENT AND DEVICE DEFICIENCY REPORTING  ............................  18 
12.1 Definitions  ................................ ................................ ................................ ................................ ..... 18 
12.2 Definition of Adverse Event Severity  ................................ ................................ ...........................  20 
12.3 Definition of Relationship to Investigational Device  ................................ ................................ .... 20 
12.4 Management of Adverse Events  ................................ ................................ ................................ ... 21 
12.4.1  Adverse Events Assessments  ................................ ................................ .........................  21 
12.4.2  Adverse Event Documentation  ................................ ................................ .......................  21 
12.4.3  Reporting of SAE and/or UADE  ................................ ................................ ....................  21 
12.5 Management of Device Deficiencies  ................................ ................................ ............................  21 
12.5.1  Device Deficiency Assessment  ................................ ................................ ......................  21 
12.5.2  Device Deficiency Documentation  ................................ ................................ .................  21 
12.5.3  Reporting of Device Deficiencies  ................................ ................................ ..................  22 
13 RISK / BENEFIT ANALYSIS  ................................ ................................ ................................ ..... [ADDRESS_321738]  ................................ ...... 24 
14.2.4  Informed Consent  ................................ ................................ ................................ ...........  25 
14.2.5  Privacy of Personal Data  ................................ ................................ ................................  25 
15 ADMINISTRATIVE REQUIREMENTS  ................................ ................................ .....................  26 
15.1 Protocol Amendments  ................................ ................................ ................................ ...................  26 
15.2 Protocol Deviations  ................................ ................................ ................................ .......................  26 
15.3 Regulatory Documentation  ................................ ................................ ................................ ...........  26 
15.3.1  Regulatory Approval/Notification  ................................ ................................ ..................  [ADDRESS_321739] Retention and Storage  ................................ ................................ ........................  27 
15.3.6  Device Accountability  ................................ ................................ ................................ .... 28 
15.3.7  Packaging and Labeling  ................................ ................................ ................................ . 28 
15.4 Monitoring Procedures  ................................ ................................ ................................ ..................  28 
15.5  Use of Information and Publication  ................................ ................................ ..............................  29 
15.6 Study Registration in a publicly accessible database  ................................ ................................ .... 30 
APPENDIX  A – TIME & EVENTS SCHEDULE  
APPENDIX  B – PHOTOGRAPHY  
 
Protocol CTP-BSO -[ADDRESS_321740] 
circumferen ce reduction.  
Location(s)  [ADDRESS_321741] of a single BeShape One treatment and a 
follow up period (12 weeks)  
Eligible subjects will receive [ADDRESS_321742] circu mference reduction.  
Inclusion Criteria  1. Female and male subjects ≥18 and ≤[ADDRESS_321743] 1.5 cm.  
3. 18.5 ≤ BMI ≤ 3 3  
4. Women of childbearing potential (i.e., not post -menopausal 
or surgically sterilize) must have a negati ve urine 
Protocol CTP-BSO -[ADDRESS_321744] de -identified images  of the treated areas  
taken  for possible use in publications and presentations.  
Exclusion Criteria  1. Pregnant women, intending to become pregnant during the  
study , less than 12 months after delivery , breastfeeding, or  
less than 6 weeks after completing breastfeeding;  
2. Participation in a clinical study of another investigational 
device or drug involving the same anatomical site within 
the last 3 months, or, if it does not involve the same 
anatomical site, at the discretion of the researcher.  
3. Subjects with significant systemic disease, such as ongoing 
hyperlipi[INVESTIGATOR_035], diabetes mellitus, hepatitis or other liver 
disease, HIV -positive status, blood coagulopathy or 
excessive bleeding, autoimmune or connective tissue 
disease, and malignant neoplasms; undergoing chronic 
steroid or immunosuppressive therapy.  
4.  Subject having or undergoing any form of treatment for 
active cancer, or having a history of skin cancer or any 
other cancer in the areas to be treated, including presence 
of malign ant or pre‐malignant pi[INVESTIGATOR_80436] . 
5. An implanted pacemaker or any other implantable active 
device anywhere in the body.  
6. Subjects with thyroid disease and / or metabolic syndrome.  
7. Unstable weight within the last 6 months (i.e. + 3% weight 
change in the past six months) . 
8. Local skin pathologies or natural structure loss in the treated 
area (hernia) and / or loss of sensation or dysesthesia in 
the treated area.  
9. Previous body contouring procedures in the treatment area 
within the past [ADDRESS_321745] 3 
months.  
15. Any condition that, at the researcher's discretion, renders 
the subject unsuitable for participation in a clinical 
research study.  
Duration of Study  Up to 4 months  (including screening period and two follow up 
visits  at 6 and 12 weeks after the treatment )  
Primary Endpoint  To evaluate the reduction in  waist circumference following 
treatment  with the BeShape One device  at the final 12-week  
follow -up visit compared to baseline.  
Secondary 
Endpoints  1. Waist circumference reduction at [ADDRESS_321746] improvements measured independently by [CONTACT_264749] 
(6 wk and 12 wk).  
3. Subject satisfaction using a 5-point  Likert scale at each 
follow up visit (6 wk and 12 wk).  
4. Investigator satisfaction using the Clinical Global Aesthetic 
Improvement scale at each follow up visit ( 6 wk and 12 
wk). 
5. Subject comfort/pain level, assessed after treatment using a 
pain scale . 
Exploratory 
Endpoints  To evaluate the reduction in  abdominal fat thickness at 6- and 
12-weeks  post treatment . 
Safety Endpoint  Number, severity and type of adverse events recorded 
throughout the study and post treatment phase (immediate and 
delayed response).  
Study Sponsor  BeShape Technologies Ltd.  
Hataas 20, Kfar Saba  
Israel  
 
Protocol CTP-BSO -[ADDRESS_321747] Operating Procedure  
WHO  World Health Organization  
W Watt (Output Electric Power)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol CTP-BSO -[ADDRESS_321748] 2024  
8 
 1 INTRODUCTION  
A growing number of people seek cosmetic solutions for the removal of excess weight. 
These solutions include surgical trends of abdominoplasties, Brachioplasty and 
liposuction procedures. The latter is used for the removal of excess fat tissues in specific 
body areas for body shapi[INVESTIGATOR_007], combined with several modifications including ultrasound 
(US) and laser (Brown SA, 2009) .  Due to limitations and complications resulting in 
death, there has been a significant decrease in the performance of these procedures 
(Garcia O, 2013) , and during this period, a significant number of noninvasive body 
contouring devices have been introduced to the aesthetic surgery market. Many 21st -
century aesthetic surgery patients now seek noninvasive or minimally invasive procedures 
with minimal downtime in exchange for limited aesthetic outcomes. Current nonsurgical 
procedures employ mechanical vacuum massage, lasers, radiofrequency, ultrasound, or 
low-level energy infrared light  (Sasaki GH, 2014) . Some of these devices may create a 
temporary effect but are unable to present any scientific or preclinical evidence (histology 
or gross pathology) of fat cell disruption.  
Currently, a significant number of noninvasive in -use devices are ultrasonic energy -
based. The use of ultrasonic energy in aesthetic body contouring, dating back to the late 
1980s, popularized the concept of ultrasound -assisted liposuction (UAL), and introduced 
the techniques to the [LOCATION_003] in 1993 (Garcia O, 2013; Manstein D L.H., 2008).  
US used for body sculpting can be divided into two broad categories: relatively low -
frequency nonthermal ultrasound and high intensity focused thermal ultrasound. With 
nonthermal US, a low frequency is chosen to increase the likelihood of cavitation while 
generating little heat through absorption mechanisms. The high -intensity focused 
ultrasound (HIFU) can be highly f ocused to conﬁne the cavitation effects to the focal 
zone of the ultrasonic beam. Thermal HIFU delivers high frequency (2MHz) ultrasonic 
energy to subcutaneous tissue, producing heat capable of disrupting adipose tissue and 
thermally modifying collagen (Jewell, 2011) .  
The early generations of US devices for use in body contouring were associated with 
increased complication rates, which were mostly attributed to the high ultrasonic energy 
output associated with these devices (Garcia O, 2013; Manstein D, 2008) . 
The ultrasonic energy used by [CONTACT_264750] (Solta Medical, Inc., Hayward, CA, 
[LOCATION_003]) is an example of High-Frequency Thermal Ultrasound, which is generated by [CONTACT_264751] a  
speciﬁed depth and location (Ter Haar G, 2007)  at temperatures reaching [ADDRESS_321749] circumference reduction . Safety of the device 
was also evaluated. There were no unanticipated adverse device events, and clinical 
laboratory tests did not reveal any abnormalities (Mark L. Jewell, 2011)  
Protocol CTP-BSO -[ADDRESS_321750] (CW) ultrasonic energy to the adipose tissue at a 
temperature of 480C. There is far less information regarding the effects of non -focused 
and weakly focused US on adipose tissue and its ability to disrupt fat cells. Non -focused 
US has typi[INVESTIGATOR_264743], where changes in cellular activity and 
cell membrane permeability have been reported (Garcia O, 2013) . 
A unique feature of the BeShape OneTM is the vacuum feature. The activated vacuum 
effectively fixes the target tissue in the treated area inside the cup -shaped chamber of the 
device applicator . This tissue fixation in the applicator  allows  the transmi ssion of  the 
ultrasound energy parallel to the body surface, rather than perpendicular , thereby 
[CONTACT_264752] .  
An example of a device utilizing vacuum  to achieve its desired affects in lipolysis 
(breakdown of fat)  is the Zeltiq CoolSculpting System (Allergan + Zeltiq Aesthetics, 
Pleasanton, CA [LOCATION_003]) . It is a thermoelectric cooling and heating device using 
Cryolipolysis  technology  to target fat cells . Similar to BeShape's technology, the device 
includes a cup-shaped applicator with two cooling panels that is applied to the treatment 
area. The tissue is drawn into the handpi[INVESTIGATOR_264744]  (Nils Krueger, 2014) . The vacuum applicator draws 
tissue into the applicator cup and holds the tissue against the cooling surfaces of the 
applicator . Clinical findings  with the Zeltiq CoolSculpting system  utilizing  vacuum and 
surface applicators  demonstrate d that use of the device  safely and effectively induce d 
cold-assisted lipolysis with co lder temperatures down to -15°C, resulting in shorter 
duration treatment . 
The purpose of the current clinical study is to evaluat e the safety and effective ness of 
treatment with the investigational high-intensity non -focused BeShape One US device on 
waist circumferen ce reduction . 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol CTP-BSO -[ADDRESS_321751] 2024  
10 
 2 DEVICE DESCRIPTION  
2.1 General Device Description  
The BeShape OneTM system consists of hardware and software, these elements are 
integrated in the BeShape OneTM console and applicator/handpi[INVESTIGATOR_13959].  BeShape OneTM is 
supplied as a kit, with a console and [ADDRESS_321752] circumference reduction  in adult  population.  
 
4 RATIONALE FOR STUDY  
A growing number of people seek cosmetic solutions for the removal of excess weight.  
Surgical solutions  such as  abdominoplasties, Brachioplasty and liposuction procedures  
are available but these include limitations and complications sometimes even resulting in 
death . Therefore , there has been a significant decrease in the performance of these 
invasive procedures (Garcia O, 2013)  and nonsurgical solutions are at need.  
 
Although no nonsurgical procedure has been accepted as the gold standard as of yet, 
cryolipolysis is considered to be both safe and effective, with a high patient satisfaction 
rate of up to 73% after one treatment. This rate is comparable with that of HIFU and 
acoustic wave therapy (62.3% and 64%, respectively). However, the latter modalities are 
associated with either a higher rate of adverse events and pain or a high number of up to 
eight treatments necessary to achie ve the desired effect (Nils Krueger, 2014)  . 
 
The noninvasive BeShape One device offer s an alternative approach for waist 
circumference reduction using a high intensity non -focused US technology.  The current 
proposed study will evaluate  the s afety and efficacy of the BeShape One device in 
effectively reducing waist circumference in adult population.  
 
 
Protocol CTP-BSO -[ADDRESS_321753] circumference following BeShape treatment at the final 
follow -up visit compared to baseline.  
 
5.2 Secondary Endpoints  
The secondary objectives of the study are as follows:  
• Waist circumference reduction at 6 week follow up visits compared to baseline, . 
• Subject improvement as measured independently by [CONTACT_264753] ( 6 wk and 12 wk).  
• Subject satisfaction using a 5-point  Likert scale at each follow up visit  (6 wk and 12 
wk). 
• Investigator satisfaction using the Clinical Global Aesthetic Improvement scale at 
each follow up visit (6 wk and 12 wk).  
• Subject comfort/pain level, assessed after treatment using a pain scale . 
 
5.[ADDRESS_321754] 
treatment phase (immediate and delayed response) , including skin reactions (erythema, 
edema, irritation, etc.) . 
 
 
6 SELECTION OF STUDY POPULATION  
The intention is to enroll 70 patients who meet all eligibility criteria. Evaluation of the 
study participant inclusion/exclusion criteria will be based on the review of clinical 
medical records and documented patient interviews conducted by [CONTACT_264754] . 
 
To be enrolled in the study, patients mus t meet ALL of the inclusion criteria and NONE 
of the exclusion criteria  designated below.  
 
Protocol CTP-BSO -[ADDRESS_321755] 2024  
12 
 6.1 Inclusion Criteria:  
 
1. Female and male subjects ≥ 18 and ≤[ADDRESS_321756] 1.5 cm.  
3. 18.5 ≤ BMI ≤ 3 3  
4. Women of childbearing potentia l (i.e., not post -menopausal or surgically sterilize) 
must have a negative urine pregnancy test. Participating women of childbearing 
potential must be using a medically acceptable form of birth control for at least [ADDRESS_321757] de -identified images of the treated areas taken for possible use in 
publications and presentations.  
6.2 Exclusion Criteria  
1. Pregnant women, intending to become pregnant during the study , less than 12 months  
after delivery , breastfeeding, or less than 6 weeks after completing breastfeeding;  
2. Participation in another clinical study of another investigational device or drug 
involving the same anatomical site within the last 3 months, or, if it does not involve 
the same anatomical site, at the discretion of the researcher.  
3. Subjects with significant systemic disease, such as ongoing hyperlipi[INVESTIGATOR_035], diabetes 
mellitus, hepatitis or other liver disease, HIV -positive status, blood coagulopathy or 
excessive bleeding, autoimmune or connective tissue disease, and malignant 
neoplasms; undergoing chronic steroid or immunosuppressive therapy.  
4. Subject having or undergoing any form of treatment for active cancer, or having a 
history of skin cancer or any other cancer in the areas to be treated, including 
presence of ma lignant or pre‐malignant pi[INVESTIGATOR_80436] . 
5. An implanted pacemaker or any other implantable active device anywhere in the body.  
6. Subjects with thyroid disease and / or metabolic syndrome.  
7. Unstable weight within the last 6 months (i.e. + 3% weight change in the past six 
months) . 
8. Local skin pathologies or natural structure loss in the treated area (hernia) and / or loss 
of sensation or dysesthesia in the treated area.  
9. Previous body contouring procedures in the treatment area within the past [ADDRESS_321758] 2024  
13 
 15. Any condition that, at the researcher's discretion, renders the subject unsuitable for 
participation in a clinical research study.  
 
6.3 Informed Consent  
Written informed consent will be obtained from each study patient prior to enrollment 
into the study.  A written informed consent (approved by [CONTACT_264755].  and 
the Ethics Committee) must be signed and dated by [CONTACT_102] (or legally authorized 
representative, if appropriate), and the investigator.  Patients will be given a copy of the 
signed informed consent document.  The signed informed consent will be retained with 
the study records at the site. It is the responsibility of the Investigator to assure that 
informed consent is obtained from each patient in accordance with GCP guidelines.  
Subjects may withdraw their consent to participate in the study at any time without 
prejudice. The investigator may withdraw a subject if, in his clinical judgement, it is in 
the best interest of the subject or if the subject cannot comply with the protocol.  
 
[ADDRESS_321759] 
circumference reduction.  
All subjects will undergo an assessment of their general health. A single treatment 
utilizing the BeShape OneTM device will be administered.  
During the follow -up period, visits will be conducted as follows: 6 weeks (6wk FU), and 
12 weeks (12wk FU) post treatment. Subject’s waist circumference will be measured at 
baseline ( before treatment ) and at each of the follow up visits. Circumference reduction 
will be assessed at each post baseline visit. Additionally, investigator and subject 
assessments will be completed at each follow up visit. Photography of the treatment areas 
will be performed under visible light conditions of the front, right, left and back view of 
the subjects at the baseline visit (before first treatment) and at the last follow -up visit 
(12wk FU).  
 
[ADDRESS_321760] 4  
abdomen/flanks treatment areas  and up to [ADDRESS_321761] any outstanding 
findings on the CRF before  proceed ing to the next area of treatment .  
Immediately after completion of the procedure  (after all treatment areas have been 
treated) , the following evaluations and measurements will be performed:  
* Assessment of adverse events, including any skin reaction  (erythema, edema, 
irritation, etc.) or any other side effects ; 
* Pain assessment . 
 
All findings will be recorded on the Adverse Events form.   
 
9 STUDY PROCEDURES  
9.1 Overview  
Patient visits may occur within a + 2 days deviation  from the scheduled time.  
Efficacy rating scales to be used in the study include:  
• Waist circumference measurement  
• Abdominal fat thickness measurements  
• Global Aesthetic Improvement scale  (GAI)  
• Clinical Global Aesthetic Improvement scale  (CGAI)  
Safety evaluations will include a pain scale and  adverse event monitoring  throughout the 
study . Number, severity and type of adverse events will be recorded throughout treatment 
and follow -up phases.  
9.[ADDRESS_321762] for eligibility to participate. 
The inclusion/exclusion criteria will be reviewed, the subject’s medical history  and a 
physical examination of the subject ’s general health including vital signs will be 
performed. In addition, there will also be an examination of the subject’s skin in  the 
treatment area .  
The subject will review the informed consent form and the study will be explained to the 
subject including all risks, potential benefits, procedures, visit requirements, and other 
alternative treatment options. If the subject qualifies and wishes to participate, they will 
complete the ICF with a signature [CONTACT_3670]. The original will be retained with subject’s 
records and a copy will be provided to the subject.  
Protocol CTP-BSO -[ADDRESS_321763] using 
pre-defined scale questionnaire. The subjects will answer this questionnaire at each 
follow -up visit ( 6wk FU , and 12wk FU) . 
 
9.6.[ADDRESS_321764] using pre-
defined scale questionnaire. The subjects will answer this questionnaire at each follow -up 
visit ( 6wk FU , and 12wk FU) . 
 
9.6.3 Investigator Satisfaction using the Clinical Global Aesthetic Scale  
Satisfaction assessment will be performed by [CONTACT_264756] a pre -defined 
scale questionnaire. The investigator will answer this questionnaire at each follow -up visit 
(6wk FU, and 12wk FU)  
 
9.6.[ADDRESS_321765] 2024  
16 
 10 PATIENT COMPLETION / WITHDRAWAL  
10.[ADDRESS_321766] will be withdrawn from the study for any of the following reasons:  
• Withdrawal of consent  
• Subject is not compliant with requirements of the study, including inclusion and 
exclusion criteria.  
• The investigator believes that for safety reasons (e.g. an adverse event) it is in the 
best interest of the patient to stop the study . 
• The study is prematurely stopped or halted (e.g. clinical halt)  
Subjects enrolled in the study can discontinue their participation at any time for any 
reason without prejudice or reduction in the quality of their medical care. The 
investigators or sponsor can terminate a subject's participation in this study to protect the 
subject's health or if the subject fails to follow directions resulting in noncompliance to 
study procedures. Subjects who fail to complete the study will be replaced and will not be  
considered evaluable.  
 
[ADDRESS_321767] 
circumference.  
11.2.2  Secondary Endpoints  
The secondary endpoints are  
• Change from baseline to [ADDRESS_321768] circumference . 
• Global Aesthetic Improvement scale at [ADDRESS_321769] rated improvement.  
• Satisfaction scale at [ADDRESS_321770] 
rated satisfaction.  
• Clinical Global Aesthetic Improvement  scale at 6 weeks and 12 weeks following 
treatment  measuring investigator rated improvement . 
• Pain score after treatment measuring subject comfort/pain level.  
Protocol CTP-BSO -[ADDRESS_321771] 
treatment phase , including skin reactions (erythema, edema, irritation, etc.) . 
Safety will also be assessed with vital signs . 
11.[ADDRESS_321772]  circumference 12 weeks after treatment . 
  
11.4 Sample Size Determination  
A total samples size of 70 subjects should be enrolled into the study.  
 
11.5 Analysis Data Sets  
11.5.1  Safety  Analysis Set  
All subjects who received treatment will be included in the safety  analysis set . The safety 
analysis set  will be used for the summary and analyses of all safety endpoints.  
11.5.2  Full Analysis Set (FAS)  
The full analysis set (FAS) includes all eligible subjects who  are enrolled in the study,  
received treatment and have at least one post treatment waist circumference measurement .  
The FAS will be used for the summary and analyses of the primary, secondary and 
exploratory endpoints.  
11.5.3  Per Protocol (PP) Analysis Set  
The per protocol (PP) analysis set will consist of all subjects from the FAS without any 
major protocol violations.   The PP analysis set will be used for a sensitivity analysis of 
the primary endpoint.  
11.6 Statistical Methods  
11.6.1  Randomization  
This is a one arm study thus no randomization will be performed.  
11.6.2  Disposition of Subjects /Data  
The numbers of subjects who were enrolled will be provided. A list of discontinued 
subjects together with the reasons for discontinuation will  be presented.  
Protocol CTP-BSO -[ADDRESS_321773] and presented descriptively.  
11.6.5  Safety Analyses  
All safety analyses will be performed on the Safety Analysis Population.  The safety 
assessment will be based on the incidence, severity and relationship to treatment of the 
adverse events.  
All Serious Adverse Events (SAEs) will be listed and discussed on a subject -by-subject  
basis.  
Vital signs will be presented descriptively by [CONTACT_765].    
 
[ADDRESS_321774] 
Operating Procedures (SOPs) in conformity with regulatory requirements worldwide to 
ensure appropriate reporting of safety information. All clinical studies conducted by [CONTACT_264757].  
 
12.1 Definitions  
The definitions provided below are in compliance with ISO [ZIP_CODE] ([ADDRESS_321775] edition) 
and 21 CFR 812.3  
• Adverse Event (AE)  
An adverse event is any untoward medical occurr ence, unintended disease or injury, or 
untoward clinical signs in subjects, users or other persons, whether or not related to the 
investigational medical device and whether anticipated or unanticipated.   
This definition includes any occurrence that is new in onset or aggravated in severity or 
frequency from the baseline condition, or abnormal results of diagnostic procedures, 
including laboratory test abnormalities.  
This definition also includes events related to the control and to the procedures involved.  
Note: The sponsor collects adverse events starting with the signing of the informed 
consent.  
 
Protocol CTP-BSO -[ADDRESS_321776] 2024  
19 
 • Adverse Device Effect (ADE)  
An adverse event related to the use of an investigational medical device.  
This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deployment, implantation, installation or operation or any 
malfunction of the investigational device.  
This definition includes any event resulting from use error or from intentional misuse of 
the investigational device.  
• Serious Adverse Event  (SAE)  
An adverse event that led to any of the following : 
o death  
o serious deterioration in the health of the subject, users or other persons as 
defined by [CONTACT_10980]:  
o a life-threatening  illness or injury or a permanent impairment of a body 
structure or  
o a body function including chronic diseases or  
o in-patient or prolonged hospi[INVESTIGATOR_26109]  
o medical or surgical intervention to prevent life -threatening illness or injury 
or permanent impairment to a body structure or function  
o foetal distress, foetal death, a congenital abnormality, or birth defect including  
physical or mental impairment  
Note: Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is also appropriate in situations other than those listed above. For example, 
important medical events may not be immediately life threatening or result in death or 
hospi[INVESTIGATOR_264745]. Any adverse event is considered a serious 
adverse event if it is associated with clinical signs or symptoms judged by [CONTACT_264758] a significant clinical impact.  
• Serious Adverse Device Effect (SADE)  
An adverse device effect (ADE) that has resulted in a ny of the consequences 
characteristic of a serious device event (SAE).  
• Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE)  
A serious adverse device effect (SADE) which by [CONTACT_5942], incidence, severity or 
outcome has not been identified in the current version of the risk assessment.  
Note: Anticipated serious adverse device effect (ASADE) is an effect which by [CONTACT_5942], 
incidence, severity or outcome has been identified in the current version of the risk 
assessment.  
• Device Deficiency  (DD)  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, 
usability, safety and performance.  
Protocol CTP-BSO -[ADDRESS_321777] 2024  
20 
 This definition includes malfunctions, use errors and inadequacy in the information 
supplied by [CONTACT_143143].  
This definition includes device deficiencies related to the investigational device or 
control.  
 
12.2 Definition of Adverse Event Severity  
For all adverse events, the severity of the adverse event will be determined by [CONTACT_1275], using the following terms:  
• Mild  
A mild adverse event is one in which the subject is aware of the event, but it is easily 
tolerated without intervention.  
• Moderate  
A moderate adverse event is one that causes sufficient discomfort to interfere with usual 
activities . 
• Severe  
A severe adverse event is one that results in the inability to perform usual activities.  
 
12.3 Definition of Relationship to Investigational Device  
For all adverse events, the relationship to study device and/or procedure will be 
determined by [CONTACT_093], using the following terms:  
• Probably related:  
Follows a reasonable temporal sequence from study device delivery / retrieval, and 
cannot be reasonably explained by [CONTACT_8129]’s clinical data or 
the surgical procedure applied.  
• Possibly related:  
Follows a reasonable temporal sequence from study device delivery / retrieval, but could 
have been produced by [CONTACT_102]’s clinical state or by [CONTACT_264759].  
• Probably not related:  
Temporal association is such that the study device is not likely to have had any 
reasonable association with the observed event.  
• Not related:   
No relationship to study device activation is perceived.  
 
Protocol CTP-BSO -[ADDRESS_321778] experience an adverse event, an assessment of the situation will be 
initiated by [CONTACT_5984], the PI [INVESTIGATOR_264746]. The sponsor will be contact[CONTACT_264760]. The AE will be documented 
and reported per the sponsor SOPs, IRB and regulation requirements.  
12.4.2  Adverse Event Documentation  
The adverse event will be recorded in the Case Report Forms and will include the 
following information:  
• Type of effect (AE, ADE, SAE, UADE, ASADE, SADE)  
• Date of onset and resolution  
• Severity  
• Seriousness (yes/no)  
• Relationship to device/procedure  
• Anticipated (yes/no)  
• Treatment given and/or action taken  
12.4.3  Reporting of SAE and/or UADE  
All SAE's, SADE, ASADE and UADE will be reported in writing to the PI, sponsor and 
IRB within [ADDRESS_321779] 2024  
22 
 12.5.3  Reporting of Device Deficiencies  
The PI [INVESTIGATOR_264747], IRB and regulatory authorities (if applicable) device 
deficiencies that could have led to a serious adverse device effect within 72 hours of 
knowledge of the event.  
 
13 RISK / BENEFIT ANALYSIS  
13.[ADDRESS_321780] circumference reduction in adult population. The risks to patients 
resulting from potential device hazards and associated with the study procedures/devices 
have been analyzed using the Risk Management Standard - ISO [ZIP_CODE]. The different 
types of hazards were identified and evaluated using risk assessment numerical 
parameters. Applicable controls for the risks were analyzed. After the implementation of 
appropriate risk control measures, the level of risk was re -evaluated and found to be 
acceptable. Below is a summary of some of the key hazards and applicable control 
measures.  
 
Patient Injury Risk:  The BeShape One device may cause over -heating related patient 
injuries such as skin burns, blistering and erythema.  
Patient Injury Risk Mitigation : The over -heating related injuries are mitigated by [CONTACT_264761] a predetermined time. In addition, mitigation is achieved by 
[CONTACT_264762], including 
constant monitoring of the energy level during treatment and cooling water and 
therapeutic heating temperature control. The device has also been tested in pre -clinical 
settings, demonstrating and proving the safety of the device.  
 
Biocompatibility Risk:  The device components and/or materials may present a 
biocompatibility risk (irritation, allergic reaction, etc.) if they contact [CONTACT_13935]' body.  
Biocompatibility Risk Mitigation : The risk of biocompatibility is mitigated as all the 
materials that come in contact [CONTACT_264763]. The 
device is non -invasive and only comes in contact [CONTACT_264764].  
 
Use Risk:  The operator may perform the treatment incorrectly (due to use error or SW 
bug) and/or apply excessive treatment duration, potentially causing patient injury.  
Use Risk Mitigation : The BeShape One device includes a floor standing portable console 
and touch screen which indicates if the acoustic energy is turned on or off. The user can 
stop the acoustic energy transmission at any time by [CONTACT_264765]/off button or the 
emergency button. Furthermore, prior to each treatment a system test is performed. 
Comprehensive software validation, proper operator training, proper instructions for use 
and electrical safety testing are additional mitigations for this use risk.  
  
Protocol CTP-BSO -[ADDRESS_321781] 2024  
23 
 Performance Risk:  The BeShape One device may lead to ineffective treatment due to 
vacuum mechanism failure.  
Performance Risk Mitigation : This risk is mitigated by [CONTACT_264766]. 
The system is configured to stop its operation if good skin contact [CONTACT_264767]. 
Further mitigations include pre -clinical studies and SW validation.  
 
System Failure Risk:  The BeShape One device may fail to operate due to system 
malfunction.  
System Failure Risk  Mitigation : The BeShape Once device is calibrated during 
manufacturing. In addition, the manufacturer supplies it with a tissue -mimicking phantom 
for periodic user tests.  
 
In summary, there are no anticipated severe risks or serious adverse device effects. There 
are no contraindications for use in the proposed study or study population. There may be 
other risks to the subject that are associated with the device or procedure which are 
unforeseeable at this time.  
 
13.[ADDRESS_321782] circumference reduction.  
 
14 ETHICAL ASPECTS  
14.1 Study -Specific Design Considerations  
Subjects/cases will be carefully screened using the study eligibility criteria prior to 
enrollment in the study.  
 
14.2 Regulatory Ethics Compliance  
14.2.1  Statement of Compliance  
The study will be conducted in compliance the Declaration of Helsinki, ISO [ZIP_CODE], 21 
CFR 50 and 21 CFR 812 for non -significant risk device studies, applicable regulatory 
requirements and ICH Good Clinical Practice  (GCP) guidelines. The study will be 
conducted in accordance with this protocol and any regional or national regulations, as 
appropriate. The study will not commence until the approval from the IRB has been 
Protocol CTP-BSO -[ADDRESS_321783]  
Before the start of the study, the investigator will provide the IEC/IRB with current and 
complete copi[INVESTIGATOR_23747]:  
• Final protocol and if applicable, amendments  
• Informed consent form  
• Investigator's Brochure (or equivalent information) and amendments  
• Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by [CONTACT_8134]/IRB)  
• Information regarding funding, name [CONTACT_8152], institutional affiliations, and 
other potential conflicts of interest  
• Any other documents that the IEC/IRB requests to fulfill its obligation  
This study will be undertaken only after IEC/IRB has given full approval of the final 
protocol, amendments (if any), and informed consent and after the sponsor has received a 
copy of this approval. This approval letter must be dated and must clearly identify the 
documents being approved.  
During the study the investigator will send the following documents to the IEC/IRB for 
their review and approval, where appropriate:  
• Protocol amendments  
• Investigator's Brochure amendments or new edition(s)  
• Summaries of the status of the study (at least annually or at intervals stipulated in 
guidelines of the IEC/IRB)  
• Reports of any serious adverse events, if applicable  
• Deviations from or changes to the protocol  
• Notification if new investigator is responsible for the study at the site  
• Any other requirements of the IEC/IRB  
At least once a year the IEC/IRB will be asked to review and re -approve this clinical 
study. This request and approval should be documented in writ ing. At the end of the 
Protocol CTP-BSO -[ADDRESS_321784] 2024  
25 
 study, the investigator (or sponsor where required) will notify the IEC/IRB about the 
study completion.  
14.2.[ADDRESS_321785] be approved by [CONTACT_264768]/IRB. The informed consent should be in accordance 
with principles set forth in the Declaration of Helsinki, current ICH and GCP guidelines, 
applicable regulatory requirements, and sponsor policy.  
Before entry into the study, the investigator or an authorized member of the 
investigational staff must explain to potential subjects the aims, methods, reasonably 
anticipated benefits, and potential hazards of the study, and any discomfort it may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate 
will not affect the care the subject will receive for the treatment for his/her disease. 
Subjects will be told that alternative treatments are available if they refuse to take part 
and that such refusal will not prejudice future treatment. Finally,  they will be told that 
their records may be accessed by [CONTACT_264769], to the extent permitted by [CONTACT_6983](s) or regulations. By [CONTACT_264770] . 
The subject will be given sufficient time to read the informed consent form and the 
opportunity to ask questions. After this explanation and before entry into the study, 
consent should be appropriately recorded by [CONTACT_264771], subject's signature [CONTACT_264780]. After having obtained the consent, a copy of the informed consent form 
must be given to the subject.  If the subject or legally acceptable representative is unable 
to read or write, an impartial witness should be present for the entire informed consent 
process (which includes reading and explaining all written explanations) and should 
personally date and sign the inform consent form after the oral consent of the subject or 
legally acceptable representative is obtained.  
14.2.[ADDRESS_321786](s) used in this study. This data must be collected and 
processed with adequate precautions to ensure confidentiality and compliance with 
applicable data privacy protection laws and regulations.  
 
 
 
 
Protocol CTP-BSO -[ADDRESS_321787] not be implemented without prior IEC/IRB approval, or when the 
relevant competent authority has raised any grounds for non -acceptance, except when 
necessary,  to eliminate immediate hazards to the patients in which case the amendment 
must be promptly submitted to the IEC/IRB and relevant competent authority. When the 
change(s) involves only logistic or administrative aspects of the study, the IRB (and IEC 
where required) only needs to be notified.  
15.[ADDRESS_321788] be made as soon as possible in order 
to discuss the situation and agree on an appropriate course of action. Any protocol 
deviation needs to be recorded in the CRF, source documents and protocol deviation form 
and should describe the deviation and the circumstances requiring it.  
15.3 Regulatory Documentation  
15.3.1  Regulatory Approval/Notification  
This protocol and any amendment(s) must be submitted to the appropriate regulatory 
authorities in each respective country, if applicable. A study may not be initiated at a site 
until all local regulatory requirements are met.  
15.3.[ADDRESS_321789] be available and maintained during the study:  
• Approved Study Protocol and amendment(s)  
• A copy of the dated and signed written IEC/IRB approval of the protocol and any 
amendments. This approval must clearly identify the specific protocol by [CONTACT_264772].  
• An approved informed consent form  
• Regulatory authority approval or notification, if applicable  
• Documentation of investigator qualifications (e.g., curriculum vitae)  
• Completed financial disclosure form  
• Signed and dated clinical trial agreement, which includes the financial agreements  
• Other documentation required by [CONTACT_264773]-BSO -[ADDRESS_321790]/case identification register to permit easy 
identification of each subject/case during and after the study. The subject/case 
identification register will be treated as confidential. To ensure patient confidentiality, no 
copy will be made. All reports and communications relating to the study will identify 
subject/case by [CONTACT_264774]. The investigator will also complete a 
subject/case enrollment log, which reports all subject/case who were determined eligible 
for inclusion in the study.  
15.3.4  Case Report Form Completion  
All data relating to the study will be recorded on source documents/CRFs and then 
entered into an EDC with electronic CRFs (eCRFs). The case report forms and/or pre -
templated source documents will only include a subject number and initials.  Data will be 
collected in English. A black or blue pen will be used to record data on the source 
documents/CRFs. The source documents and eCRFs are to be completed at the time of 
the data collection. Recorded information should be legible and complete. Erroneous 
entries should be crossed out, corrected with the change, initialed and dated by [CONTACT_264775]. Every effort should be made to ensure that all measures 
are recorded on the source documents and eCRFs. The investigator must verify that all 
data entries on the source documents and in the eCRFs are accurate and correct. The EDC 
will include electronic CRFs and will be used to process the data collected during the 
study. The development, validation, handling, maintenance, security measures, change 
control, data backup, retention, recovery, user access, blinding etc. will be performed per 
sponsor SOPs and regulatory requirements.  
15.3.[ADDRESS_321791] Retention  and Storage  
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all 
source documents and eCRFs that support the data collected from each patient, as well as 
all study documents as specified in ISO [ZIP_CODE] Annex E, Essential clinical investigation 
documents, and all study documents as specified by [CONTACT_3605](s). The investigator/institution will take measures to prevent accidental or 
premature destruction of these documents.  
Essential documents must be retained and stored for at least [ADDRESS_321792] elapsed since the 
formal discontinuation of clinical development of the investigational products. These 
documents will be retained for a longer period if required by [CONTACT_264776]. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.  
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who 
Protocol CTP-BSO -[ADDRESS_321793] permit access to such 
report.  
15.3.6  Device Accountability  
A Device Accountability Log will be maintained for the sponsor's equipment (smart 
phones and software) documenting date of receipt, description of device (including type, 
model#, serial number or unique code, quantity and software version) and date of return 
for used and unused products. Device usage will be recorded in the CRF for each subject.  
15.3.7  Packaging and Labeling  
This study will utilize  an investigational device  and FDA cleared devices as controls. The 
sponsor is responsible for packaging and labeling of the device for delivery to the study 
site. FDA cleared devices do not require special labeling. Investigational devices or its 
immediate package shall bear a label with the following statement:  
"CAUTION – Investigational device. Limited by [CONTACT_4496] (or [LOCATION_002]) law to 
investigational use."  
The label or other labeling shall describe all relevant contraindications, hazards, adverse 
effects, interfering substances or devices, warnings and precautions.  It is the investigator's 
responsibility to ensure appropriate labeling is visible and remains intact throughout the 
life of the study.  The instructions for use (IFU) will be provided as separate documents 
from this protocol.  
15.4 Monitoring Procedures  
The sponsor is responsible for all monitoring -related procedures. The monitoring 
activities will be performed based on a written monitoring plan and will include, but not 
be limited to, descriptions of monitor qualifications, training, visit reports and reviews, 
follow up on monitoring findings and corrective actions.  
The monitoring requirements for an NSR device study is identified in 21 CFR 812.2(b) 
Abbreviated requirements. For monitoring an NSR device study, the requirement is to 
comply with [ADDRESS_321794] to monitoring:  
• Compliance to the signed agreement between the investigator and sponsor  
• The study follows the protocol and any amendments that apply  
• Compliance to any conditions of the approval imposed by [CONTACT_264777], the monitor will verify that:  
• The conditions for the study continue to be acceptable  
Protocol CTP-BSO -[ADDRESS_321795] 2024  
29 
 • Accurate, complete and current records are maintained and required reports are 
written  
• Any adverse effects are documented and reported to the sponsor and IRB as 
appropriate  
• Source data is verified and corrections are made to any inconsistencies or missing 
data found  
• Findings of non -compliance or required modifications are reviewed with the 
investigator and is presented in a written report or follow up letter  
• A monitoring report is written at the end of each monitoring visit and/or the clinical 
study  
15.5 Use of Information and Publication  
All information, including but not limited to information regarding BeShape One TM or 
the sponsor's operation (e.g., patent application, manufacturing processes, basic scientific 
data, prior clinical data, and formulation information) supplied by [CONTACT_263782], and any data generated as a result of this study, 
are considered confidential and remains the sole property of the sponsor. The investigator 
agrees to maintain this information in confidence and use this information only to 
accomplish this study, and will not use it for other purposes without the sponsor's prior 
written consent.  
The investigator understands that the information developed in the clinical study will be 
used by [CONTACT_264778] , and thus may be disclosed as required to other clinical investigators or 
regulatory agencies. To permit the information derived from the clinical studies to be 
used, the investigator is obligated to provide the sponsor with all data obtained in the 
study.  
The results of the study will be reported in a Clinical Study Report generated by [CONTACT_264779]. Any work created in 
connection with performance of the study and contained in the data that can benefit from 
copyright protection (except any publication by [CONTACT_40999]) 
shall be the property of the sponsor as author and owner of copyright in such work.  
The sponsor shall have the right to publish such data and information without approval 
from the investigator. If an investigator wishes to publish information from the study, a 
copy of the manuscript must be provided to the sponsor for review at least [ADDRESS_321796] of the study. Results will be entered at completion of the clinical study.  